PhRMA Foundation

PhRMA Foundation 2023: Postdoctoral Fellowship - Drug Discovery Targets and Pathway

N. Kitamura on behafh J.Galligan's Lab (Pharmacology and Toxicology)
K. Rahman on behafh H. Li's Lab (Pharmacology and Toxicology)

 

Only one postdoctoral applicant per lab may apply for this award.

 

Successful drug discovery involves the innovative application and integration of multiple scientific disciplines to create efficacious, safe, and differentiated treatment options for patients. The PhRMA Foundation seeks to fund novel early-stage, exploratory drug discovery research with the potential for translation to humans, including biological validation of potential drug targets, signaling pathways, or mechanisms of disease.  

Research topics could include, but are not limited to:   

  • Genomics and Proteomics  
  • Cellular and Molecular Biology  
  • Design and Generation of Pharmacological Tools   
  • In Vitro and/or In Vivo Pharmacology  
  • Protein Biochemistry  
  • Molecular Modelling  
  • Structural Biology  
  • Cell Imaging  
  • Single Cell Analysis  
  • Artificial Intelligence and Computational Approaches  

Projects that focus exclusively on single aspects such as identification of and development of assays for single targets, chemical probes, biomarkers, chemical library screening, or diagnostics will not be considered for review. Project aims should have a high likelihood of completion in the award timeframe

Funding Type
Internal Deadline
External Deadline
08/01/2023
Solicitation Type

2023 Postdoctoral Fellowship - Drug Discovery

No applicants // Limit: 1 // Tickets Available: 1 

 

The PhRMA Foundation Postdoctoral Fellowship in Drug Discovery Targets and Pathways supports individuals engaged in a multidisciplinary, collaborative research training program at an accredited U.S. university that will extend their credentials in drug discovery research. 

Successful drug discovery involves the innovative application and integration of multiple scientific disciplines to create efficacious, safe, and differentiated treatment options for patients. The PhRMA Foundation seeks to fund novel early-stage, exploratory drug discovery research with the potential for translation to humans, including biological validation of potential drug targets, signaling pathways, or mechanisms of disease.  
Research topics could include, but are not limited to:   

  • Genomics and Proteomics  
  • Cellular and Molecular Biology  
  • Design and Generation of Pharmacological Tools   
  • In Vitro and/or In Vivo Pharmacology  
  • Protein Biochemistry  
  • Molecular Modelling  
  • Structural Biology  
  • Cell Imaging  
  • Single Cell Analysis  
  • Artificial Intelligence and Computational Approaches  

Projects that focus exclusively on single aspects such as identification of and development of assays for single targets, chemical probes, biomarkers, chemical library screening, or diagnostics will not be considered for review. Project aims should have a high likelihood of completion in the award timeframe.

 

Eligibility

  • Applicants (U.S. and non-U.S. citizens) must be based at a PhD and/or MS degree-granting accredited U.S. university. 
  • Applicants have a firm commitment from a research supervisor or sponsor at their university.  
  • Applicants must hold a PhD, PharmD, MD, or appropriate terminal research doctorate. If you do not hold one at the time of application submission, please state in your extended letter when you expect to receive it, as it must be received before funding can begin. Funding can begin as early as January 1, 2024, or as late as August 1, 2024.  
  • Applicants must be within their first five years of postdoctoral study at the time of award activation. 
  • Applicants who are applying for funds to support postdoctoral work in the laboratory where their graduate work was performed will be given lower preference. One of the objectives of this fellowship is to gain new skills, and therefore, an ideal candidate will be conducting their research in a new laboratory and not where their graduate work was performed. 
  • The Foundation will not consider multiple applications for similar efforts on the same project. For instance, if a predoc, postdoc, and faculty member from the same lab are all submitting applications for proposed efforts on the same project, the efforts must be separate activities and not duplicative.
Funding Type
Internal Deadline
External Deadline
05/15/2023
Solicitation Type

PhRMA Foundation 2023: Postdoctoral Fellowship - Drug Delivery

No applicants // Limit: 1 // Tickets Available: 1 

 

UArizona may submit one application per lab may apply for this award. 

The PhRMA Foundation Postdoctoral Fellowship in Drug Delivery supports individuals engaged in a multidisciplinary, collaborative research training program at an accredited U.S. university that will extend their credentials in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology, or biomedical engineering.  Successful proposals in Drug Delivery emphasize the quantitative understanding of the principles, pathways, and/or mechanisms underlying improved or optimized: 

  • formulation composition and delivery modalities/technologies that enable more favorable transport (absorption, targeting, elimination) of drugs; and/or 
  • drug dosage forms that can be manufactured to achieve higher quality, lower cost, and greater stability or flexibility. 

Today’s drugs include biologics, small molecules, and cell and gene therapy. Delivering increasingly complex drugs demands thorough understanding of technologies and formulation approaches. 
Research that focuses on findings that can be generalized to other systems will be prioritized. Testing the delivery of a single drug by one approach is less preferred. 

 

Eligibility

  • Applicants (U.S. and non-U.S. citizens) must be based at a PhD and/or MS degree-granting accredited U.S. university. 
  • Applicants have a firm commitment from a research supervisor or sponsor at their university.  
  • Applicants must hold a PhD, PharmD, MD, or appropriate terminal research doctorate. If you do not hold one at the time of application submission, please state in your extended letter when you expect to receive it, as it must be received before funding can begin. Funding can begin as early as January 1, 2024, or as late as August 1, 2024.  
  • Applicants must be within their first five years of postdoctoral study at the time of award activation. 
  • Applicants who are applying for funds to support postdoctoral work in the laboratory where their graduate work was performed will be given lower preference. One of the objectives of this fellowship is to gain new skills, and therefore, an ideal candidate will be conducting their research in a new laboratory and not where their graduate work was performed. 
  • The Foundation will not consider multiple applications for similar efforts on the same project. For instance, if a predoc, postdoc, and faculty member from the same lab are all submitting applications for proposed efforts on the same project, the efforts must be separate activities and not duplicative.  
Funding Type
Internal Deadline
External Deadline
08/31/2023
Solicitation Type

Research Starter Grants - Health Outcomes, Pharmacology/Toxicology, Pharmaceutics, Translational Medicine and Therapeutics or Informatics

Research Starter Grants offer financial support to individuals beginning independent research careers at the faculty level. This program provides a research grant of $100,000 for one year.  Research Starter Grants support individuals in academia who do not have other substantial sources of research funding. Applicants will be judged on the scientific merit of the proposed research, and on the degree of financial need.  The “starter” aspect of the program strives to assist individuals who are establishing careers as independent investigators. The program is not offered as a means to augment an ongoing research effort. Funds may not be used for salary support.

Funding Type
Internal Deadline
External Deadline
02/01/18 for Health Outcomes, Translational Medicine and Therapeutics. 9/1/18 for remaining